Biobiggen
Biobiggen is a non-invasive prenatal chromosomal disease and monogenic disease simultaneous screening technology platform.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Biobiggen Information
Geographic Data
Address:
City: Daxing
State: Beijing
Zip:
Country: China
Financial Info
Stage:
series unknown
Raised Last:
$0
Raised Total:$0
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Biobiggen is a non-invasive prenatal chromosomal disease and monogenic disease simultaneous screening technology platform. It is focusing on the pregnancy and childbirth period, focusing on prenatal screening, supplemented by newborn screening and prenatal diagnosis, and deeply creating the most complete high-throughput prevention and control of genetic diseases and birth defects Sequencing technology series of innovative products, leading enterprises and unicorn enterprises in the subdivision field. The company is headquartered in Beijing Economic and Technological Development Zone, has an overseas research center in Houston, the United States, and an R&a;D transformation center, GMP production base, and medical testing laboratory in Beijing.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 1/2021 | Venture Round | 1 | - |
Northern Light Venture Capital Northern Light Venture Capital |
1/2021 | Venture Round | 1 | - |
Northern Light Venture Capital Northern Light Venture Capital |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
